Browsing Tag
Acalabrutinib
4 posts
AbbVie Inc. (NYSE: ABBV) wins FDA approval for Venclexta and acalabrutinib in first-line chronic lymphocytic leukemia
AbbVie Inc. secures FDA approval for Venclexta plus acalabrutinib in first-line CLL. Find out why this decision matters for patients, payers, and investors.
AstraZeneca’s CALQUENCE demonstrates enhanced efficacy in mantle cell lymphoma trial
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE…
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL
Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of…
FDA grants accelerated approval to AstraZeneca’s Calquence for mantle cell lymphoma treatment
AstraZeneca has achieved a significant milestone with the early FDA approval of Calquence (acalabrutinib) for the treatment of…